Valneva targets 2022 revenue boost of up to 70% on COVID-19 vaccine

by Reuters

– French vaccine developer Valneva targets increasing its revenues year-on-year by up to 70% thanks to a boost from its COVID-19 vaccine candidate, it said on Thursday.

The company sees 2022 revenue of between 430 million to 590 million euros ($485.73 million to $666.46 million), including 350 million to 500 million euros of COVID-19 vaccine sales, which are still subject to regulatory approvals and deliveries of their COVID vaccine candidate called VLA2001.

Valneva’s 2021 revenue soared 216% year-on-year to 348.1 million euros mainly on COVID-related revenues under a terminated agreement in Britain.

($1 = 0.8853 euros)

(Reporting by Piotr Lipinski in Gdansk; Editing by Christian Schmollinger)

Related News:  Kroger CDL Drivers in Forest Park Vote to Unionize with Teamsters

tagreuters.com2022binary_LYNXMPEI1205S-BASEIMAGE

author avatar
Reuters

You may also like

You can't access this website

Shore News Network provides free news to users. No paywalls. No subscriptions. Please support us by disabling ad blocker or using a different browser and trying again.